AmStem to begin clinical trial for cosmeceutical cream
Nevada-based AmStem, which specializes in products based on stem cell expertise that incorporates nanotechnology says the federally regulated Institutional Review Board (IRB) in North America has approved the initial clinical study of the facial cream product.
The company says that the study is expected to begin this week at the Scottsdale Institute for Cosmetic Dermatology and will last approximately two months.
"To our knowledge, this is the first US IRB approved clinical study of a cosmetic product containing extracts from human umbilical cord stem cells," said AmStem Chief Scientific Officer David Stark
"We are pleased to have the approval of an independent IRB validating our efforts to conduct an ethical, statistically validated clinical study of SteMixxTM that will protect the rights and privacy of women who will participate."
